MiR-221-induced PUMA silencing mediates immune evasion of bladder cancer cells.

Immune evasion of cancer cells is mainly due to the impaired transduction of apoptotic signals from immune cells to cancer cells, as well as inhibition of subsequent apoptosis signal cascades within the cancer cells. Over the past few decades, the research has focused more on the impaired transduction of the apoptotic signal from immune cells to cancer cells, rather than inhibition of the intracellular signaling pathways. In this study, miR‑221 inhibitor was transfected into bladder cancer cell lines 5637, J82 and T24 to repress the expression of miR‑221. As a result, the repression of miR‑221 on p53 upregulated modulator of apoptosis (PUMA) was abolished, resulting in increased expression of the pro-apoptotic Bax and reduced expression of the anti-apoptotic Bcl-2, which promotes apoptosis of bladder cancer cells. The expression of MMP-2, MMP-9 and VEGF-C were reduced, resulting in reduced invasiveness and infiltration capability of bladder cancer cells, thereby inhibiting the immune evasion of bladder cancer cells.

[1]  R. Askeland,et al.  Anti‐interleukin‐10R1 monoclonal antibody in combination with bacillus Calmette–Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti‐tumour immunity , 2014, Clinical and experimental immunology.

[2]  Han Liu,et al.  PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis , 2013, Science Signaling.

[3]  A. Filho,et al.  Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. , 2013, Cancer genomics & proteomics.

[4]  S. Ryter,et al.  Curcumin induces apoptotic cell death of activated human CD4+ T cells via increasing endoplasmic reticulum stress and mitochondrial dysfunction. , 2013, International immunopharmacology.

[5]  M. Cannataro,et al.  In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma , 2013, Oncotarget.

[6]  Richard W. Kriwacki,et al.  PUMA Binding Induces Partial Unfolding within BCL-xL to Disrupt p53 Binding and Promote Apoptosis , 2012, Nature chemical biology.

[7]  M. Esmat,et al.  The Value of Combined Use of Survivin mRNA and Matrix Metalloproteinase 2 and 9 for Bladder Cancer Detection in Voided Urine , 2012, Disease markers.

[8]  A. Boulares,et al.  Apoptotic DNA Fragmentation May Be a Cooperative Activity between Caspase-activated Deoxyribonuclease and the Poly(ADP-ribose) Polymerase-regulated DNAS1L3, an Endoplasmic Reticulum-localized Endonuclease That Translocates to the Nucleus during Apoptosis* , 2012, The Journal of Biological Chemistry.

[9]  W. Xu,et al.  A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia , 2012, Cancer Gene Therapy.

[10]  Zhihong Liu,et al.  Glutathione S-transferase P1 gene polymorphism and bladder cancer susceptibility: an updated analysis , 2012, Molecular Biology Reports.

[11]  Yuquan Wei,et al.  JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells. , 2012, The Biochemical journal.

[12]  J. Kaufman,et al.  Immune escape strategies of a contagious cancer, devil facial tumour disease , 2012 .

[13]  S. Inan,et al.  Matrix metalloproteinase (MMP-2 and MMP-9) and steroid receptor expressions in feline mammary tumors , 2012, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[14]  E. Ulukaya,et al.  The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib , 2012, Tumor Biology.

[15]  Cornelis F. M. Sier,et al.  MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients , 2012, British Journal of Cancer.

[16]  M. Swartz,et al.  VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. , 2012, Cell reports.

[17]  M. Nuzzaci,et al.  Apoptotic Effects of a Chimeric Plant Virus Carrying a Mimotope of the Hepatitis C virus Hypervariable Region 1: Role of Caspases and Endoplasmic Reticulum-Stress , 2012, Journal of Clinical Immunology.

[18]  J. Chiang,et al.  Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. , 2012, Cancer research.

[19]  C. Poyet,et al.  906 Bladder cancer micro environment influences maturation signature in lymphatic endothelial cells (LECs) by VEGF-C , 2012 .

[20]  S. Takano Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation , 2012, Brain Tumor Pathology.

[21]  B. Kandemir,et al.  Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. , 2011, Pathology, research and practice.

[22]  H. Nakayama,et al.  Apoptosis-dependent Externalization and Involvement in Apoptotic Cell Clearance of DmCaBP1, an Endoplasmic Reticulum Protein of Drosophila* , 2011, The Journal of Biological Chemistry.

[23]  T. Jiang,et al.  Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. , 2011, Oncology reports.

[24]  Yung-Hyun Choi,et al.  Methanol extract of Hydroclathrus clathratus suppresses matrix metalloproteinase-9 in T24 bladder carcinoma cells by suppressing the NF-κB and MAPK pathways. , 2011, Oncology reports.

[25]  M. Campone,et al.  c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1 , 2011, Molecular Cancer.

[26]  Barbara Majello,et al.  Myc and PI3K/AKT signaling cooperatively repress FOXO3a-dependent PUMA and GADD45a gene expression , 2011, Nucleic acids research.

[27]  K. Alitalo,et al.  VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. , 2011, Trends in molecular medicine.

[28]  R. Seiler,et al.  MMP-2 and MMP-9 in lymph-node-positive bladder cancer , 2011, Journal of Clinical Pathology.

[29]  V. Baron,et al.  Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo , 2011, The Prostate.

[30]  Zhiwei Wang,et al.  Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. , 2011, Cancer research.

[31]  P. Lin,et al.  C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α , 2011, Oncogene.

[32]  S. Ylä-Herttuala,et al.  341 VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease , 2011 .

[33]  C. Kang,et al.  PUMA is a novel target of miR-221/222 in human epithelial cancers. , 2010, International journal of oncology.

[34]  J. Cheng,et al.  MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma , 2010, Molecular Cancer.

[35]  Hui-ping Wang,et al.  siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo. , 2010, Experimental and therapeutic medicine.

[36]  Xiangyi Zheng,et al.  Inhibition of TGF-β receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase , 2010, International Urology and Nephrology.

[37]  M. Ismail,et al.  Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase‐2 in patients with bladder cancer , 2010, IUBMB life.

[38]  T. Griffith,et al.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. , 2009, European journal of pharmacology.

[39]  C. Kirkpatrick,et al.  Endothelial VEGFR-3 expression in colorectal carcinomas is associated with hematogenous metastasis. , 2009, Oncology reports.

[40]  J. Niederkorn Immune escape mechanisms of intraocular tumors , 2009, Progress in Retinal and Eye Research.

[41]  Bin Zhou,et al.  [Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. , 2009, Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi.

[42]  M. Detmar,et al.  Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. , 2009, The Journal of investigative dermatology.

[43]  P. Pääkko,et al.  Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis. , 2008, Anticancer research.

[44]  Zihua Hu,et al.  MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. , 2008, Molecular immunology.

[45]  George A Calin,et al.  Micro-RNA profiling in kidney and bladder cancers. , 2007, Urologic oncology.

[46]  T. Turpeenniemi‐Hujanen,et al.  Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. , 2007, Clinical biochemistry.

[47]  Haidong Dong,et al.  PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.

[48]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[49]  Y. Kudo,et al.  VEGF-C is associated with lymphatic status and invasion in oral cancer , 2007, Journal of Clinical Pathology.

[50]  A. Tangoku,et al.  The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer , 2006, British Journal of Cancer.

[51]  S. Harper,et al.  VEGF-C promotes survival in podocytes. , 2006, American journal of physiology. Renal physiology.

[52]  Hiroshi Sato,et al.  Roles of membrane‐type matrix metalloproteinase‐1 in tumor invasion and metastasis , 2005, Cancer science.

[53]  Jian Yu,et al.  No PUMA, no death: implications for p53-dependent apoptosis. , 2003, Cancer cell.

[54]  Federico Garrido,et al.  MHC class I antigens, immune surveillance, and tumor immune escape , 2003, Journal of cellular physiology.

[55]  D. Chopin,et al.  Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. , 2003, The American journal of pathology.

[56]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[57]  P. Krammer,et al.  Immune escape of tumors: apoptosis resistance and tumor counterattack , 2002, Journal of leukocyte biology.

[58]  K. Sugiyama,et al.  Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. , 2001, European journal of cancer.

[59]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[60]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[61]  A. Okada [Roles of matrix metalloproteinases and tissue inhibitor of metalloproteinase (TIMP) in cancer invasion and metastasis]. , 1999, Gan to kagaku ryoho. Cancer & chemotherapy.

[62]  K. Alitalo,et al.  Current biology of VEGF-B and VEGF-C. , 1999, Current opinion in biotechnology.

[63]  K. Alitalo,et al.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.

[64]  Tomoyuki Kato,et al.  Matrix metalloproteinase 9 in mucosally invasive gastric cancer , 1998, Gastric Cancer.

[65]  Brygida Berse,et al.  Vascular permeability factor (VPF, VEGF) in tumor biology , 1993, Cancer and Metastasis Reviews.

[66]  D. Tindall,et al.  Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. , 2013, Cancer research.

[67]  Xiangqi Li,et al.  Expression of survivin and VEGF-C in breast cancer tissue and its relation to lymphatic metastasis. , 2012, European journal of gynaecological oncology.

[68]  W. Shi,et al.  Matrix metalloproteinase-9 silencing by RNA interference promotes the adhesive-invasive switch in HT1080 human fibrosarcoma cells. , 2012, Clinical laboratory.

[69]  Yi-Xun Liu,et al.  Apotosis in ovary. , 2011, Frontiers in bioscience.

[70]  F. Alameda,et al.  Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. , 2011, Human pathology.

[71]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[72]  T. Tsubata Apotosis of mature B cells. , 1999, International reviews of immunology.